A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Tavapadon In Early Parkinson’s Disease (TEMPO-2 TRIAL)

  • Iansek, Robert (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 62249
NMA SSA Reference Number: SSA/62249/MonH-2020-227555(v1)
Monash Health Reference: RES-20-0000-203A
StatusActive
Effective start/end date8/09/20 → 7/09/25

Keywords

  • clinical trial
  • treatment efficacy
  • treatment safety
  • Parkinson's disease
  • phase 3 study